Literature DB >> 23327123

History of Orbivirus research in South Africa.

Daniel W Verwoerd1.   

Abstract

In the early colonial history of South Africa, horses played an important role, both in general transportation and in military operations. Frequent epidemics of African horsesickness (AHS) in the 18th century therefore severely affected the economy. The first scientific research on the disease was carried out by Alexander Edington (1892), the first government bacteriologist of the Cape Colony, who resolved the existing confusion that reigned and established its identity as a separate disease. Bluetongue (BT) was described for the first time by Duncan Hutcheon in 1880, although it was probably always endemic in wild ruminants and only became a problem when highly susceptible Merino sheep were introduced to the Cape in the late 18th century. The filterability of the AHS virus (AHSV) was demonstrated in 1900 by M'Fadyean in London, and that of the BT virus (BTV) in 1905 by Theiler at Onderstepoort, thus proving the viral nature of both agents. Theiler developed the first vaccines for both diseases at Onderstepoort. Both vaccines consisted of infective blood followed by hyper-immune serum, and were used for many years. Subsequent breakthroughs include the adaptation to propagation and attenuation in embryonated eggs in the case of BTV and in mouse brains for AHSV. This was followed by the discovery of multiple serotypes of both viruses, the transmission of both by Culicoides midges and their eventual replication in cell cultures. Molecular studies led to the discovery of the segmented double-stranded RNA genomes, thus proving their genetic relationship and leading to their classification in a genus called Orbivirus. Further work included the molecular cloning of the genes of all the serotypes of both viruses and clarification of their relationship to the viral proteins, which led to much improved diagnostic techniques and eventually to the development of a recombinant vaccine, which unfortunately has so far been unsuitable for mass production.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23327123     DOI: 10.4102/jsava.v83i1.532

Source DB:  PubMed          Journal:  J S Afr Vet Assoc        ISSN: 1019-9128            Impact factor:   1.474


  4 in total

1.  Rapid generation of replication-deficient monovalent and multivalent vaccines for bluetongue virus: protection against virulent virus challenge in cattle and sheep.

Authors:  Cristina C P Celma; Mark Boyce; Piet A van Rijn; Michael Eschbaumer; Kerstin Wernike; Bernd Hoffmann; Martin Beer; Andy Haegeman; Kris De Clercq; Polly Roy
Journal:  J Virol       Date:  2013-07-03       Impact factor: 5.103

2.  Consensus Sequence of 27 African Horse Sickness Virus Genomes from Viruses Collected over a 76-Year Period (1933 to 2009).

Authors:  A Christiaan Potgieter; Isabella M Wright; Alberdina A van Dijk
Journal:  Genome Announc       Date:  2015-09-10

3.  A synthetic biology approach for a vaccine platform against known and newly emerging serotypes of bluetongue virus.

Authors:  Sandro Filipe Nunes; Claude Hamers; Maxime Ratinier; Andrew Shaw; Sylvie Brunet; Pascal Hudelet; Massimo Palmarini
Journal:  J Virol       Date:  2014-08-20       Impact factor: 5.103

4.  Virus and host factors affecting the clinical outcome of bluetongue virus infection.

Authors:  Marco Caporale; Luigina Di Gialleonorado; Anna Janowicz; Gavin Wilkie; Andrew Shaw; Giovanni Savini; Piet A Van Rijn; Peter Mertens; Mauro Di Ventura; Massimo Palmarini
Journal:  J Virol       Date:  2014-07-02       Impact factor: 5.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.